Court upholds AbbVie's patents on blockbuster cancer drug Imbruvica, generics unlikely until 2032
AbbVie’s blockbuster cancer drug Imbruvica may hold onto its monopoly for at least another decade, thanks to a court ruling Thursday that found a generic drugmaker’s Imbruvica knockoff infringed on AbbVie’s patents.
The Delaware district court found that Alvogen, whose subsidiary Alvotech is also still going after AbbVie’s other massive blockbuster drug Humira in Illinois district court, made claims on particular Imbruvica patents that “are not invalid” and Alvogen “infringes each of the asserted claims.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.